Business Description
Invex Therapeutics Ltd
Compare
Compare
Traded in other countries / regions
IXC.Australia IPO Date
2019-07-04Description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.05 | |||||
| 9-Day RSI | 53.78 | |||||
| 14-Day RSI | 49.72 | |||||
| 6-1 Month Momentum % | -19.83 | |||||
| 12-1 Month Momentum % | -20.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.29 | |||||
| Quick Ratio | 22.29 | |||||
| Cash Ratio | 21.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -21.51 | |||||
| ROA % | -20.73 | |||||
| ROCE % | -24.59 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.36 | |||||
| Price-to-Tangible-Book | 1.41 | |||||
| EV-to-EBIT | -1.97 | |||||
| EV-to-EBITDA | -1.97 | |||||
| EV-to-FCF | -1.6 | |||||
| Price-to-Net-Current-Asset-Value | 1.41 | |||||
| Price-to-Net-Cash | 1.45 | |||||
| Earnings Yield (Greenblatt) % | -50.64 |
How Invex Therapeutics Ltd (ASX:IXC) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Invex Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.08 | ||
| Beta | 1.44 | ||
| Volatility % | 39.26 | ||
| 14-Day RSI | 49.72 | ||
| 14-Day ATR (A$) | 0.026054 | ||
| 20-Day SMA (A$) | 0.45225 | ||
| 12-1 Month Momentum % | -20.49 | ||
| 52-Week Range (A$) | 0.425 - 0.75 | ||
| Shares Outstanding (Mil) | 75.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Invex Therapeutics Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Invex Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Invex Therapeutics Ltd Frequently Asked Questions
What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
The current price of ASX:IXC is A$0.47. The 52 week high of ASX:IXC is A$0.75 and 52 week low is A$0.43.
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
The next earnings date of Invex Therapeutics Ltd(ASX:IXC) is .
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
Invex Therapeutics Ltd(ASX:IXC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
